中文簡介

《人類基因治療》是一本涵蓋基因治療各個(gè)方面的多學(xué)科雜志。該雜志通過提供最新的研究和技術(shù)突破，對DNA、RNA和細(xì)胞療法進(jìn)行了深入報(bào)道。人類基因治療為科學(xué)和臨床信息提供了一個(gè)中心論壇，包括倫理、法律、監(jiān)管、社會(huì)和商業(yè)問題，使治療程序的進(jìn)步和進(jìn)步能夠改善患者的結(jié)果，并最終治愈疾病。該期刊分為三個(gè)部分。人類基因療法是其旗艦，每年出版12期?！禜GT Methods》是一本雙月刊，主要研究基因治療在產(chǎn)品檢測和開發(fā)中的應(yīng)用。HGT臨床發(fā)展是一份季刊，作為發(fā)布與細(xì)胞和基因治療產(chǎn)品的監(jiān)管審查和商業(yè)開發(fā)相關(guān)的數(shù)據(jù)的場所。完整的覆蓋范圍包括:向量發(fā)展的改善運(yùn)載系統(tǒng)細(xì)胞療法小型核酸療法，包括RNAi臨床試驗(yàn)和動(dòng)物模型臨床協(xié)議臨床前動(dòng)物和體外研究評估用于支持臨床應(yīng)用的基因和細(xì)胞治療產(chǎn)品的安全性臨床試驗(yàn)，包括結(jié)果證實(shí)性或陰性的臨床試驗(yàn)與基因和細(xì)胞治療產(chǎn)品的商業(yè)開發(fā)相關(guān)的熱點(diǎn)問題《人類基因療法》被美國特殊圖書館協(xié)會(huì)生物醫(yī)學(xué)與生命科學(xué)部評選為近100年來生物學(xué)和醫(yī)學(xué)領(lǐng)域最具影響力的期刊之一。人類基因治療、HGT方法和HGT臨床開發(fā)由麻省大學(xué)醫(yī)學(xué)院醫(yī)學(xué)博士特倫斯·r·弗洛特主編;Deput歐洲編輯Nathalie Cartier，醫(yī)學(xué)博士，INSERM，和Thierry VandenDriessche，博士，布魯塞爾自由大學(xué)(VUB);美國佛羅里達(dá)大學(xué)醫(yī)學(xué)院鮑威爾基因治療中心副編輯Barry J. Byrne醫(yī)學(xué)博士，斯坦福大學(xué)醫(yī)學(xué)院Mark A. Kay醫(yī)學(xué)博士;人類基因治療編輯高廣平，麻省大學(xué)醫(yī)學(xué)院博士;方法編輯Hildegard Buning，博士，漢諾威醫(yī)學(xué)院;臨床發(fā)展編輯James M. Wilson，醫(yī)學(xué)博士，賓夕法尼亞大學(xué)醫(yī)學(xué)院，基因治療項(xiàng)目;以及其他主要調(diào)查人員。查看整個(gè)編輯委員會(huì)。觀眾:遺傳學(xué)家、醫(yī)學(xué)遺傳學(xué)家、分子生物學(xué)家、病毒學(xué)家、實(shí)驗(yàn)研究人員、實(shí)驗(yàn)醫(yī)學(xué)專家等。人類基因治療和HGT方法提供“即時(shí)在線”出版后72小時(shí)接受

投稿網(wǎng)址：http://www.liebertpub.com/forauthors/human-gene-therapy/19/

英文簡介

Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.Complete coverage includes: Improvements in vector developments Delivery systems Cell therapy Small nucleic acid therapeutics, including RNAi Clinical trials and animal models Clinical protocols Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications Clinical trials including those in which the results are confirmatory or negative Topical issues related to the commercial development of gene and cell therapy productsHuman Gene Therapy was voted one of the most influential journals in Biology and Medicine over the last 100 years by the Biomedical & Life Sciences Division of the Special Libraries Association.Human Gene Therapy, HGT Methods, and HGT Clinical Development are under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School; Deput Editors Europe Nathalie Cartier, MD, INSERM, and Thierry VandenDriessche, PhD, Free University of Brussels (VUB); Deputy Editors U.S. Barry J. Byrne, MD, PhD, Powell Gene Therapy Center, University of Florida, College of Medicine and Mark A. Kay, MD, PhD, Stanford University School of Medicine; Human Gene Therapy Editor Guangping Gao, PhD, University of Massachusetts Medical School; Methods Editor Hildegard Büning, PhD, Hannover Medical School; Clinical Development Editor James M. Wilson, MD, PhD, University of Pennsylvania School of Medicine, Gene Therapy Program; and other leading investigators. View the entire editorial board.Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance